Group 1 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash purchase and capital increase, making Huiru a subsidiary [1] - Huiru Technology specializes in the research, production, and sales of high-performance electrolytic copper foil, including lithium battery copper foil and electronic circuit copper foil [1] Group 2 - Medike's shareholder plans to reduce holdings by no more than 1% of the company's shares, amounting to approximately 410.93 million shares [2] - Huadong Medicine's subsidiary, Daor Biotechnology, has its product DR10624 included in the list of breakthrough therapeutic varieties, targeting severe hypertriglyceridemia [3] Group 3 - Fangsheng Pharmaceutical received a notice of non-compliance from the Hunan Provincial Drug Administration regarding its raw material drug production [4] - Yanjing Co. is planning a major asset restructuring, leading to a temporary suspension of its stock [5] - Xianle Health intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [6] Group 4 - Huate Gas shareholders plan to collectively reduce their holdings by no more than 2% of the company's shares [7] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [8] Group 5 - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for the year 2025 [10] - Jinzongzi Wine anticipates a net loss for the 2025 fiscal year, although the loss is expected to narrow compared to the previous year [11] - Hebang Bio forecasts a net loss for 2025 due to anticipated asset impairment provisions [12] Group 6 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, estimating a profit of 160 million to 200 million yuan [13] - Kosen Technology and Weiyuan Co. both project net losses for 2025 [14][15] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, with a year-on-year increase of 9.41% [16] Group 7 - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [17] - Zhongheng Group anticipates a net loss for 2025 [18]

Core Viewpoint - On January 9, Hebang Biotechnology's stock price remained unchanged, with a trading volume of 355 million yuan, indicating a stable market position despite fluctuations in financing activities [1]. Financing Summary - On January 9, Hebang Biotechnology had a financing buy-in amount of 54.7361 million yuan and a financing repayment of 62.7429 million yuan, resulting in a net financing outflow of 8.0068 million yuan [1]. - The total financing and securities balance for Hebang Biotechnology reached 576 million yuan, with the financing balance of 568 million yuan accounting for 2.76% of the circulating market value, which is above the 50th percentile level over the past year [1]. - In terms of securities lending, 30,100 shares were repaid, while 35,900 shares were sold, with a selling amount of 83,600 yuan calculated at the closing price [1]. Company Overview - Hebang Biotechnology, established on August 1, 2002, and listed on July 31, 2012, is located in Leshan, Sichuan Province. The company specializes in the manufacturing of pesticides and pesticide intermediates, fine chemical products, intelligent glass, special glass, and the development of soda ash and ammonium chloride [1]. - The revenue composition of Hebang Biotechnology includes 85.89% from chemical products, 17.61% from photovoltaic glass and other products, 6.74% from mineral products, and 5.02% from other businesses [1]. Financial Performance - As of September 30, the number of shareholders for Hebang Biotechnology was 196,500, a decrease of 1.99% from the previous period, while the average circulating shares per person increased by 2.03% to 44,939 shares [2]. - For the period from January to September 2025, Hebang Biotechnology reported a revenue of 5.927 billion yuan, a year-on-year decrease of 13.02%, and a net profit attributable to shareholders of 93.1085 million yuan, down 57.93% year-on-year [2]. Dividend Information - Since its A-share listing, Hebang Biotechnology has distributed a total of 1.205 billion yuan in dividends, with 553 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder of Hebang Biotechnology is the Penghua CSI Sub-Segment Chemical Industry Theme ETF Link A, holding 92.7878 million shares as a new shareholder [3]. - The fifth largest shareholder, the Southern CSI 500 ETF, holds 90.0899 million shares, a decrease of 2.1844 million shares from the previous period [3]. - The Hong Kong Central Clearing Limited is the sixth largest shareholder, holding 89.2826 million shares, an increase of 16.0908 million shares from the previous period [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603077 证券简称：和邦生物 公告编号：2026-003 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 2025年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经四川和邦生物科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年度归属于上市公 司股东的净利润将出现亏损，主要系公司预计需计提资产减值准备导致。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作及资产减值测试 工作，尽快披露资产减值准备公告及2025年度业绩预告。资产减值准备公告相关数据请以公司年报审计 机构认可且经公司董事会审议确认的数据为准。公司2025年度财务数据请以公司正式披露的经审计后的 2025年年度报告为准。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站(www.sse.com.cn)，有关公司信息均以公司在上述指定媒体披露信息为准，敬请广大 ...

Group 1: Stock Trading and Corporate Actions - Jia Mei Packaging's stock will resume trading on January 12, 2026, after a price increase of 230.48% from December 17, 2025, to January 6, 2026, which led to a temporary suspension for investigation [1] - Yanjiang Co. continues to suspend its stock trading due to uncertainties related to a potential major asset restructuring, with a trading plan expected to be disclosed by January 19, 2026 [1] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [4] - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [4] - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital [4] Group 2: Mergers and Acquisitions - Defu Technology has terminated its acquisition of 100% of Luxembourg Copper Foil due to additional restrictions imposed by the Luxembourg Ministry of Economy [2] - Defu Technology intends to acquire at least 51% of Huiru Technology through cash purchase and capital increase, with Huiru becoming a subsidiary post-transaction [3] Group 3: Financial Performance and Forecasts - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, with automotive parts business growth offset by challenges in the home appliance sector [7] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [8] - Qu Mei Home expects negative profit figures for 2025, with a reported loss of approximately 66.93 million yuan for the first nine months of 2025 [9] - Jinzhongzi Liquor forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [10] - Sichuang Electronics predicts a net loss of 265 million to 340 million yuan for 2025, attributed to competitive pressures and delayed customer orders [11] - Wansheng Co. anticipates a net loss for 2025 [12] - Weiyuan Co. expects a net loss for 2025 [13] - Kosen Technology forecasts a net loss for 2025 due to market demand fluctuations and strategic adjustments [13] - Zhongheng Group predicts a net loss for 2025 [13] - Xiantan Co. reported a chicken product sales revenue of 530 million yuan in December 2025, a year-on-year increase of 9.41% [13] Group 4: Shareholder Actions - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades between February 4 and April 30, 2026 [14] - Meidike's shareholder intends to reduce holdings by up to 1% through centralized bidding [14]

公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证 券日报》及上海证券交易所网站(www.sse.com.cn)，有关公司信息均以公司在上 述指定媒体披露信息为准，敬请广大投资者注意投资风险。 特此公告。 四川和邦生物科技股份有限公司董事会 2026 年 1 月 12 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经四川和邦生物科技股份有限公司（以下简称"公司"）财务部门初步测算， 预计 2025 年度归属于上市公司股东的净利润将出现亏损，主要系公司预计需计 提资产减值准备导致。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财 务核算工作及资产减值测试工作，尽快披露资产减值准备公告及 2025 年度业绩 预告。资产减值准备公告相关数据请以公司年报审计机构认可且经公司董事会审 议确认的数据为准。公司 2025 年度财务数据请以公司正式披露的经审计后的 2025 年年度报告为准。 | 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2026-003 | | --- | -- ...

和邦生物表示，公司将严格遵循相关规定，加快推进财务核算工作及资产减值测试工作，尽快披露资产 减值准备公告及2025年度业绩预告。资产减值准备公告相关数据以公司年报审计机构认可且经公司董事 会审议确认的数据为准。公司2025年度财务数据以公司正式披露的经审计后的2025年年度报告为准。 北京商报讯（记者 马换换 王蔓蕾）1月11日晚间，和邦生物（603077）披露公告称，经公司财务部门初 步测算，预计2025年度归属净利润将出现亏损，主要系公司预计需计提资产减值准备导致。 ...

Group 1 - Jia Mei Packaging's stock will resume trading on January 12, 2026, after completing a review due to a 230.48% price increase from December 17, 2025, to January 6, 2026 [1] - Yan Jiang Co. continues to suspend trading as it plans to acquire assets, with a disclosure expected by January 19, 2026 [2] - Defu Technology terminated its acquisition of 100% of Luxembourg Copper Foil due to restrictions from the Luxembourg Ministry of Economy, with a refund of €17.4047 million expected [3] Group 2 - Defu Technology plans to acquire at least 51% of Huiru Technology through cash and capital increase, with Huiru focusing on high-performance electrolytic copper foil [4] - Shangluo Electronics' application for issuing convertible bonds has been accepted by the Shenzhen Stock Exchange [5] - Xianle Health intends to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy and capital strength [6] Group 3 - Hangyu Technology plans to sell up to 752,800 repurchased shares to supplement working capital, with a potential cancellation of unsold shares [7] - Fangsheng Pharmaceutical's production facility failed a GMP compliance check, but it will not significantly impact operations [8][9] - East China Pharmaceutical's subsidiary's product has been included in the list of breakthrough therapeutic varieties for severe hypertriglyceridemia [10] Group 4 - Dechang Co. expects a net profit decrease of 51% to 61% for 2025, primarily due to competitive pressures and foreign exchange losses [12] - Hebang Bio anticipates a net loss for 2025 due to asset impairment provisions [13] - Qu Mei Home expects a net loss for 2025, with significant negative figures reported for the first nine months [14] Group 5 - Jinzongzi Wine forecasts a net loss for 2025, although the loss is expected to narrow compared to the previous year [15] - Sichuan Electronics expects a net loss of between 265 million to 340 million yuan for 2025, attributed to market competition and delayed orders [16] - Wansheng Co. anticipates a net loss for 2025 [17] - Weiyuan Co. also expects a net loss for 2025 [19] - Kosen Technology predicts a net loss for 2025 due to low capacity utilization and strategic adjustments [20] - Zhongheng Group expects a net loss for 2025 [21] Group 6 - Xiantan Co. reported a 9.41% year-on-year increase in chicken product sales revenue to 530 million yuan in December 2025 [22] Group 7 - Huate Gas shareholders plan to reduce their holdings by up to 2% through block trades [24] - Meidike shareholders plan to reduce their holdings by up to 1% through market transactions [25]

格隆汇1月11日丨和邦生物(603077.SH)公布，经四川和邦生物科技股份有限公司(以下简称"公司")财务 部门初步测算，预计2025年度归属于上市公司股东的净利润将出现亏损，主要系公司预计需计提资产减 值准备导致。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作及资产减值测试 工作，尽快披露资产减值准备公告及2025年度业绩预告。资产减值准备公告相关数据请以公司年报审计 机构认可且经公司董事会审议确认的数据为准。公司2025年度财务数据请以公司正式披露的经审计后的 2025年年度报告为准。 ...

人民财讯1月11日电，和邦生物（603077）1月11日公告，经财务部门初步测算，预计2025年度归属于上 市公司股东的净利润将出现亏损，主要系公司预计需计提资产减值准备导致。 【资料图】 关键词： 财经频道 财经资讯 ...

和邦生物(603077)1月11日公告，经财务部门初步测算，预计2025年度归属于上市公司股东的净利润将 出现亏损，主要系公司预计需计提资产减值准备导致。 ...